dc.contributor.author | Demmelmaier, Ingrid | |
dc.contributor.author | Brooke, Hannah L. | |
dc.contributor.author | Henriksson, Anna | |
dc.contributor.author | Mazzoni, Anne-Sophie | |
dc.contributor.author | Bjørke, Ann Christin Helgesen | |
dc.contributor.author | Igelström, Helena | |
dc.contributor.author | Ax, Anna-Karin | |
dc.contributor.author | Sjövall, Katarina | |
dc.contributor.author | Hellbom, Maria | |
dc.contributor.author | Pingel, Ronnie | |
dc.contributor.author | Lindman, Henrik | |
dc.contributor.author | Johansson, Silvia | |
dc.contributor.author | Velikova, Galina | |
dc.contributor.author | Raastad, Truls | |
dc.contributor.author | Buffart, Laurien M. | |
dc.contributor.author | Åsenlöf, Pernilla | |
dc.contributor.author | Aaronson, Neil K. | |
dc.contributor.author | Glimelius, Bengt | |
dc.contributor.author | Nygren, Peter | |
dc.contributor.author | Johansson, Birgitta | |
dc.contributor.author | Börjeson, Sussanne | |
dc.contributor.author | Berntsen, Sveinung | |
dc.contributor.author | Nordin, Karin | |
dc.date.accessioned | 2021-09-15T08:03:37Z | |
dc.date.available | 2021-09-15T08:03:37Z | |
dc.date.created | 2021-06-17T14:33:07Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Demmelmaier, I., Brooke, H. L., Henriksson, A., Mazzoni, A.-S., Bjørke, A. C. H., Igelström, H., Ax, A.-K., Sjövall, K., Hellbom, M., Pingel, R., Lindman, H., Johansson, S., Velikova, G., Raastad, T., Buffart, L. M., Åsenlöf, P., Aaronson, N. K., Glimelius, B., Nygren, P., Johansson, B., Börjeson, S., Berntsen, S. & Nordin, K. (2021). Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial. Scandinavian Journal of Medicine & Science in Sports, 31 (5), 1144-1159. | en_US |
dc.identifier.issn | 1600-0838 | |
dc.identifier.uri | https://hdl.handle.net/11250/2777320 | |
dc.description.abstract | Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low-to-moderate intensity with BCS (n = 145). The 6-month exercise intervention included supervised resistance training and home-based endurance training. CRF was assessed by Multidimensional Fatigue Inventory (MFI, five subscales score range 4-20), and Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F, score range 0-52). Multiple linear regression for main factorial effects was performed according to intention-to-treat, with post-intervention CRF as primary endpoint. Overall, 577 participants (mean age 58.7 years) were randomized. Participants randomized to high- vs low-to-moderate-intensity exercise had lower physical fatigue (MFI Physical Fatigue subscale; mean difference −1.05 [95% CI: −1.85, −0.25]), but the difference was not clinically important (ie <2). We found no differences in other CRF dimensions and no effect of additional BCS. There were few minor adverse events. For CRF, patients undergoing (neo-)adjuvant treatment for breast, prostate or colorectal cancer can safely exercise at high- or low-to-moderate intensity, according to their own preferences. Additional BCS does not provide extra benefit for CRF in supervised, well-controlled exercise interventions. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | John Wiley & Sons | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2021 The Author(s) | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Helsefag: 800 | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850 | en_US |
dc.source.pagenumber | 1144-1159 | en_US |
dc.source.volume | 31 | en_US |
dc.source.journal | Scandinavian Journal of Medicine & Science in Sports | en_US |
dc.source.issue | 5 | en_US |
dc.identifier.doi | https://doi.org/10.1111/sms.13930 | |
dc.identifier.cristin | 1916447 | |
dc.relation.project | The Swedish Cancer Society: 150841 | en_US |
dc.relation.project | The Swedish Research Council: KDB/9514 | en_US |
dc.relation.project | The Nordic Cancer Union: 2015 | en_US |
dc.relation.project | The Oncology Department Foundations Research Fund in Uppsala: 2016, 2017 | en_US |
dc.description.localcode | Paid Open Access | en_US |
dc.description.localcode | UNIT agreement | en_US |
cristin.qualitycode | 2 | |